<DOC>
	<DOCNO>NCT02953041</DOCNO>
	<brief_summary>The study assess effect two drug , glycopyrronium indacaterol , take either monotherapy combination , methacholine dose-response curve . This allow elucidation mechanism drug human participant .</brief_summary>
	<brief_title>Effect LAMA uLABA Methacholine Dose-response Curve</brief_title>
	<detailed_description>This randomize , double-blind , three-way crossover study test glycopyrronium ( Seebri® ) vs. indacaterol ( Onbrez® ) vs. glycopyrronium+indacaterol . The MCT method use two-minute tidal breathing dose protocol . The investigator plan enroll thirty participant , fifteen asthmatic fifteen non-asthmatics participant . - Asthmatic Participants Procedure : Each participant undergo total twelve MCh challenge . Each MCh challenge stop response MCh reach plateau , participant 's FEV1 drop 40 % baseline , high concentration MCh ( 128mg/mL ) administer , participant wish stop ( e.g . due discomfort ) . For purpose study , plateau define last 3 consecutive data point fall within 5 % . The first day test take approx . 3hrs . entail participant undergo MCh challenge determine baseline MCh PC20 . They self-administer content two Breezhaler inhaler . If take one monotherapies , one inhaler contain active treatment ( 50mcg glycopyrronium 5mcg indacaterol ) inhaler contain placebo . For combination treatment arm , inhaler contain active drug ( one 50mcg glycopyrronium one 75mcg indacaterol ) . The identity treatment administer unknown participant study staff . Participants undergo MCT post-treatment 1 hr. , 24 hrs. , 48 hr . Testing 24 48 hr . take approximately 1-1.5 hr . Therefore , participant must attend lab roughly time day three consecutive day treatment arm . Following minimum 10-day washout treatment administration , procedure repeat second study treatment . Following second 10-day washout , procedure repeat third study treatment . - Non-Asthmatic Participants Procedure : Each non-asthmatic participant undergo single MCh challenge , take approx . 1-1.5 hr . This allow generation `` normal '' MCh DRC curve compare asthmatic data . The MCh challenge stop response MCh reach plateau , participant 's FEV1 drop 40 % baseline , high concentration MCh ( 128mg/mL ) administer , participant wish stop .</detailed_description>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Methacholine Chloride</mesh_term>
	<criteria>men woman age 18 old stable mildtomoderate asthma baseline methacholine PC20 le equal 8mg/mL FEV1 great equal 65 % predict ( asthmatic participant ) baseline methacholine PC20 great 16mg/mL ( healthy participant ) use longacting bronchodilator longacting muscarinic antagonist within 30 day Visit 1 pregnant lactate cardiovascular , prostate , kidney urinary retention problem respiratory illness within 4 week Visit 1 allergeninduced asthma exacerbate within 4 week Visit 1 hypokalemia diabetes glaucoma smoker exsmokers great 10 pack year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>